| Literature DB >> 18177500 |
Janet W Hartley1, Leonard H Evans, Kim Y Green, Zohreh Naghashfar, Alfonso R Macias, Patricia M Zerfas, Jerrold M Ward.
Abstract
The mouse macrophage-like cell line RAW264.7, the most commonly used mouse macrophage cell line in medical research, was originally reported to be free of replication-competent murine leukemia virus (MuLV) despite its origin in a tumor induced by Abelson MuLV containing Moloney MuLV as helper virus. As currently available, however, we find that it produces significant levels of ecotropic MuLV with the biologic features of the Moloney isolate and also MuLV of the polytropic or MCF class. Newborn mice developed lymphoma following inoculation with the MuLV mixture expressed by these cells. These findings should be considered in interpretation of increasingly widespread use of these cells for propagation of other viruses, studies of biological responses to virus infection and use in RNA interference and cell signalling studies.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18177500 PMCID: PMC2253558 DOI: 10.1186/1742-4690-5-1
Source DB: PubMed Journal: Retrovirology ISSN: 1742-4690 Impact factor: 4.602
Figure 1MuLV p30 expressed by RAW264.7 cells in a formalin-fixed, paraffin-embedded cell pellet. (Avidin biotin IHC, ×1000).
Comparative Pathogenicity of 264.7MuLVs and Mo-MuLV in Mice
| NIH Swiss | Mo-MuLV | 104.4 | 6/6 | 87 +/- 16 | 100 | 4 | 0 | 24 | 0 |
| 102.2 | 10/10 | 93 +/- 13 | 100 | 10 | 0 | 0 | 0 | ||
| RAW264.7 cell-free supernatant | 101.0 | 5/7 | 259 +/- 68 | 71 | 3 | 0 | 1 | 15 | |
| 102.5 | 12/15 | 163 +/- 68 | 80 | 5 | 4 | 3 | 0 | ||
| 264.7-MuLV, SC-1 passage | 102.2 | 3/3 | 146 +/- 24 | 100 | 2 | 1 | 0 | 0 | |
| None | - | 0/5 | |||||||
| BALB/c | Mo-MuLV | 104.4 | 5/5 | 98 +/- 14 | 100 | 5 | 0 | 0 | 0 |
| RAW264.7 cell-free supernatant | 101.0 | 2/2 | 255 | 100 | 1 | 0 | 1 | 0 | |
| 102.5 | 7/12 | 168 +/- 53 | 58 | 4 | 24 | 1 | 0 | ||
| 264.7-MuLV SC-1 passage | 102.2 | 5/5 | 216 +/- 84 | 100 | 4 | 0 | 0 | 16 | |
| None | - | 0/4 | |||||||
1 pfu/mouse of ecotropic MuLV, based on XC plaque titration in SC-1 cells; polytropic MuLV titer not determined.
2 number of mice positive for hematopoietic disease/number inoculated.
3 LL, lymphoblastic lymphoma;, T, T-cell lineage; B, B-cell lineage; erythroid, erythroleukemia (PAX5 and CD3 negative).
4 One case also had early Thymic T-LL.
5 Mast cell tumor, spleen and bone marrow (366d post-inoculation).
6 Early splenic marginal zone lymphoma (295d post-inoculation) ; also very early T-LL in thymus.
Figure 2MuLV p30 expression in spleen 8 weeks post injection of 264.7-MuLV, SC-1 prior to lymphoma development (IHC, hematoxylin, ×100).
Figure 3MuLV p30 in splenic follicular B-cells and megakaryocytes in a mouse injected with 264.7-MuLV and that developed thymic lymphoma at 119 days (IHC, hematoxylin, ×200).
Figure 4Thymic lymphoma induced by 264.7-MuLV, 164 days post injection. Note large spleen.
Figure 5Thymic lymphoma in 264.7-MuLV infected mouse showing CD3+ lymphoma cells in lung metastases (IHC, hematoxylin, ×200).
Figure 6PAX5 expression in bone marrow metastases of a B-cell lymphoma induced by RAW 264.7-MuLV (IHC, hematoxylin, ×100).